# A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

> **NCT04440176** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 309 (actual)

## Conditions studied

- Meningococcal Vaccine

## Interventions

- **BIOLOGICAL:** MenABCWY
- **BIOLOGICAL:** Saline

## Key facts

- **NCT ID:** NCT04440176
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-17
- **Primary completion:** 2024-01-05
- **Final completion:** 2024-01-05
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440176, "A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04440176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*